Gr-md-02 | search
Click here to view Gr-md-02 news from 60+ newspapers.
Bookmark or Share- Targeting galectin-driven regulatory circuits in cancer and fibrosisGR-MD-02 (18) (renamed belapectin by Galectin Therapeutics) (Fig. 4), a pectin-derived galactoarabino-rhamnogalacturonate substituted with predominantly β(1–4)-d-galactose and α(1–5)-l ...
- The therapeutic potential of galectin-3 inhibition in fibrotic diseaseAs a result galectin-3 inhibitors are being developed as a potential therapy for NASH and a proposed galectin-3 inhibitor GR-MD-02 (belapectin) improved histopathologic changes of NASH fibrosis in rodent models (Traber et al., 2013; Traber and Zomer, 2013).
- About Belapectin – Galectin TherapeuticsBelapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars.
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With ...GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies. We performed a phase 2b, randomized trial of the safety and efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension.
- Galectin TherapeuticsGalectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases. Learn More
More
